{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:42:46Z","timestamp":1787773366810,"version":"build-2784847793"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jad.2024.08.154","type":"journal-article","created":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T14:44:21Z","timestamp":1724510661000},"page":"597-605","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Cost-effectiveness of pharmacogenetic screening in the management of major depressive disorder in the Spanish Healthcare System"],"prefix":"10.1016","volume":"365","author":[{"given":"Javier","family":"Lopez-Saavedra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Abad-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2024.08.154_bb0005","unstructured":"American Psychological Association (Ed.). (2019). Clinical practice guideline for the treatment of depression across three age cohorts. https:\/\/www.apa.org\/depression-guideline\/guideline.pdf (accessed 29 October 2022)."},{"key":"10.1016\/j.jad.2024.08.154_bb0010","doi-asserted-by":"crossref","unstructured":"Anderson, H. D., Thant, T. M., Kao, D. P., Crooks, K. R., Mendola, N. D., & Aquilante, C. L. (2022). Pharmacogenetic testing among patients with depression in a US managed care population. Clin. Transl. Sci., 15(7), 1644-1653doi:https:\/\/doi.org\/10.1111\/cts.13279.","DOI":"10.1111\/cts.13279"},{"issue":"6","key":"10.1016\/j.jad.2024.08.154_bb0015","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s40273-021-01021-w","article-title":"The increasing economic burden with additional steps of pharmacotherapy in major depressive disorder","volume":"39","author":"Arnaud","year":"2021","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.jad.2024.08.154_bb0020","article-title":"Clinical utility of pharmacogenetics in a psychiatric and primary care population","author":"Bohlen","year":"2022","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.jad.2024.08.154_bb0025","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.2903","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants","author":"Bousman","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.jad.2024.08.154_bb0030","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12955-021-01723-x","article-title":"Health state utility values in major depressive disorder treated with pharmacological interventions: a systematic literature review","volume":"19","author":"Brockbank","year":"2021","journal-title":"Health Qual. Life Outcomes"},{"issue":"9","key":"10.1016\/j.jad.2024.08.154_bb0035","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s40261-022-01182-2","article-title":"Cost-utility analysis of Pharmacogenetic testing based on CYP2C19 or CYP2D6 in major depressive disorder: assessing the drivers of different cost-effectiveness levels from an Italian societal perspective","volume":"42","author":"Carta","year":"2022","journal-title":"Clin. Drug Investig."},{"issue":"1","key":"10.1016\/j.jad.2024.08.154_bb0040","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1186\/s12888-021-03601-8","article-title":"Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression","volume":"21","author":"Degerlund Maldi","year":"2021","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jad.2024.08.154_bb0045","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jad.2020.10.049","article-title":"Cost-effectiveness of genetic and clinical predictors for choosing combined psychotherapy and pharmacotherapy in major depression","volume":"279","author":"Fabbri","year":"2021","journal-title":"J. Affect. Disord."},{"issue":"5","key":"10.1016\/j.jad.2024.08.154_bb0050","first-page":"370","article-title":"Cost burden of treatment resistance in patients with depression","volume":"16","author":"Gibson","year":"2010","journal-title":"Am. J. Manag. Care"},{"issue":"8","key":"10.1016\/j.jad.2024.08.154_bb0055","first-page":"726","article-title":"Cost-effectiveness of a Pharmacogenetic test to guide treatment for major depressive disorder","volume":"24","author":"Grossl","year":"2018","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"1","key":"10.1016\/j.jad.2024.08.154_bb0060","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/cpt.597","article-title":"Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update","volume":"102","author":"Hicks","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jad.2024.08.154_bb0065","doi-asserted-by":"crossref","unstructured":"Husereau, D., Drummond, M., Augustovski, F., de Bekker-Grob, E., Briggs, A. H., Carswell, C., Caulley, L., Chaiyakunapruk, N., Greenberg, D., Loder, E., Mauskopf, J., Mullins, C. D., Petrou, S., Pwu, R.-F., Staniszewska, S., & CHEERS 2022 ISPOR Good Research Practices Task Force. (2022). Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 25(1), 3\u20139. doi:https:\/\/doi.org\/10.1016\/j.jval.2021.11.1351.","DOI":"10.1016\/j.jval.2021.11.1351"},{"issue":"4","key":"10.1016\/j.jad.2024.08.154_bb0070","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41397-021-00249-1","article-title":"Economic evaluation in psychiatric pharmacogenomics: a systematic review","volume":"21","author":"Karamperis","year":"2021","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.jad.2024.08.154_bb0075","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jad.2019.12.005","article-title":"European clinical practice guidelines for depression in adults: are they good enough?","volume":"263","author":"Medina","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2024.08.154_bb0080","unstructured":"Ministerio de Sanidad, Consumo y Bienestar Social. (2017). Encuesta Nacional de Salud de Espa\u00f1a (ENSE) 2017."},{"key":"10.1016\/j.jad.2024.08.154_bb0085","author":"Ortega-Eslava"},{"key":"10.1016\/j.jad.2024.08.154_bb0090","doi-asserted-by":"crossref","unstructured":"Oslin, D. W., Lynch, K. G., Shih, M. -C., Ingram, E. P., Wray, L. O., Chapman, S. R., Kranzler, H. R., Gelernter, J., Pyne, J. M., Stone, A., Du Vall, S. L., Lehmann, L. S., Thase, M. E., PRIME Care Research Group, Aslam, M., Batki, S. L., Bjork, J. M., Blow, F. C., Brenner, L. A., ... Wood, A. E. (2022). Effect of Pharmacogenomic testing for drug-gene interactions on medication selection and remission of symptoms in major depressive disorder: the PRIME care randomized clinical trial. JAMA, 328(2), 151. doi:https:\/\/doi.org\/10.1001\/jama.2022.9805.","DOI":"10.1001\/jama.2022.9805"},{"key":"10.1016\/j.jad.2024.08.154_bb0095","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jad.2021.08.036","article-title":"Economic impact of treatment resistant depression: a retrospective observational study","volume":"295","author":"P\u00e9rez-Sola","year":"2021","journal-title":"J. Affect. Disord."},{"issue":"484","key":"10.1016\/j.jad.2024.08.154_bb0100","first-page":"491","article-title":"The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: a meta-analysis","volume":"241","author":"Rosenblat","year":"2018","journal-title":"J. Affect. Disord."},{"issue":"11","key":"10.1016\/j.jad.2024.08.154_bb0105","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2024.08.154_bb0110","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1477-7525-2-20","article-title":"Usefulness of EQ-5D in assessing health status in primary care patients with major depressive disorder","volume":"2","author":"Sapin","year":"2004","journal-title":"Health Qual. Life Outcomes"},{"issue":"2","key":"10.1016\/j.jad.2024.08.154_bb0115","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1176\/appi.ajp.157.2.229","article-title":"Multiple recurrences of major depressive disorder","volume":"157","author":"Solomon","year":"2000","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.jad.2024.08.154_bb0120","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/0272989X9301300409","article-title":"Markov models in medical decision making: a practical guide","volume":"13","author":"Sonnenberg","year":"1993","journal-title":"Med. Decis. Making"},{"issue":"1","key":"10.1016\/j.jad.2024.08.154_bb0125","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41398-022-01847-8","article-title":"Clinical utility of combinatorial pharmacogenomic testing in depression: a Canadian patient- and rater-blinded, randomized, controlled trial","volume":"12","author":"Tiwari","year":"2022","journal-title":"Transl. Psychiatry"},{"issue":"4","key":"10.1016\/j.jad.2024.08.154_bb0130","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/hec.3633","article-title":"Estimating a cost-effectiveness threshold for the Spanish NHS","volume":"27","author":"Vallejo-Torres","year":"2018","journal-title":"Health Econ."},{"key":"10.1016\/j.jad.2024.08.154_bb0135","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.euroneuro.2021.04.022","article-title":"Epidemiology and costs of depressive disorder in Spain: the EPICO study","volume":"50","author":"Vieta","year":"2021","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2024.08.154_bb0140","unstructured":"WHO. (2021). Fact sheet: Depression. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/depression (accessed September 2022)."},{"key":"10.1016\/j.jad.2024.08.154_bb0145","unstructured":"World Health Assembly, 65. (2012). Global burden of mental disorders and the need for a comprehensive, coordinated response from health and social sectors at the country level: Report by the Secretariat (p. Provisional agenda item 13.2. World Health Organization."},{"issue":"12","key":"10.1016\/j.jad.2024.08.154_bb0150","doi-asserted-by":"crossref","first-page":"962","DOI":"10.3390\/brainsci10120962","article-title":"Treatment-resistant depression in a real-world setting: first interim analysis of characteristics, healthcare resource use, and utility values of the FondaMental cohort","volume":"10","author":"Yrondi","year":"2020","journal-title":"Brain Sci."},{"issue":"17","key":"10.1016\/j.jad.2024.08.154_bb0155","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.3390\/jcm10173772","article-title":"PriME-PGx: La Princesa University hospital multidisciplinary initiative for the implementation of pharmacogenetics","volume":"10","author":"Zubiaur","year":"2021","journal-title":"J. Clin. Med."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032724013880?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032724013880?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T21:38:35Z","timestamp":1725658715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032724013880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":31,"alternative-id":["S0165032724013880"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2024.08.154","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of pharmacogenetic screening in the management of major depressive disorder in the Spanish Healthcare System","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2024.08.154","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}